Hanno Svoboda
Overview
Explore the profile of Hanno Svoboda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nikolcheva T, Pagano G, Pross N, Simuni T, Marek K, Postuma R, et al.
Parkinsonism Relat Disord
. 2025 Jan;
132:107257.
PMID: 39798255
Introduction: Prasinezumab was shown to potentially delay motor progression in individuals with early-stage Parkinson's disease (PD) who were either treatment-naïve or on monoamine oxidase type B inhibitor (MAO-Bi) therapy in...
2.
Pagano G, Monnet A, Reyes A, Ribba B, Svoboda H, Kustermann T, et al.
Nat Med
. 2024 Oct;
30(12):3669-3675.
PMID: 39379705
The Phase II trial of Anti-alpha-Synuclein Antibody in Early Parkinson's Disease (PASADENA) is an ongoing double-blind, placebo-controlled trial evaluating the safety and efficacy of prasinezumab in early-stage Parkinson's disease (PD)....
3.
Pagano G, Taylor K, Anzures Cabrera J, Simuni T, Marek K, Postuma R, et al.
Nat Med
. 2024 Apr;
30(4):1096-1103.
PMID: 38622249
Prasinezumab, a monoclonal antibody that binds aggregated α-synuclein, is being investigated as a potential disease-modifying therapy in early-stage Parkinson's disease. Although in the PASADENA phase 2 study, the primary endpoint...
4.
Brundin P, Svoboda H, Bonni A, Pagano G
J Parkinsons Dis
. 2022 Nov;
12(8):2293-2296.
PMID: 36404558
No abstract available.
5.
Pagano G, Taylor K, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, et al.
N Engl J Med
. 2022 Aug;
387(5):421-432.
PMID: 35921451
Background: Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson's disease....
6.
Lipsmeier F, Taylor K, Postuma R, Volkova-Volkmar E, Kilchenmann T, Mollenhauer B, et al.
Sci Rep
. 2022 Jul;
12(1):12081.
PMID: 35840753
Digital health technologies enable remote and therefore frequent measurement of motor signs, potentially providing reliable and valid estimates of motor sign severity and progression in Parkinson's disease (PD). The Roche...
7.
Pagano G, Boess F, Taylor K, Ricci B, Mollenhauer B, Poewe W, et al.
Front Neurol
. 2021 Oct;
12:705407.
PMID: 34659081
Currently available treatments for Parkinson's disease (PD) do not slow clinical progression nor target alpha-synuclein, a key protein associated with the disease. The study objective was to evaluate the efficacy...
8.
Koser D, Thompson A, Foster S, Dwivedy A, Pillai E, Sheridan G, et al.
Nat Neurosci
. 2016 Nov;
19(12):1592-1598.
PMID: 27643431
During nervous system development, neurons extend axons along well-defined pathways. The current understanding of axon pathfinding is based mainly on chemical signaling. However, growing neurons interact not only chemically but...
9.
Hornberg H, Wollerton-van Horck F, Maurus D, Zwart M, Svoboda H, Harris W, et al.
J Neurosci
. 2013 Jun;
33(25):10384-95.
PMID: 23785151
The RNA-binding protein Hermes [RNA-binding protein with multiple splicing (RBPMS)] is expressed exclusively in retinal ganglion cells (RGCs) in the CNS, but its function in these cells is not known....
10.
Gizatullina Z, Gaynutdinov T, Svoboda H, Jerzembek D, Knabe A, Vielhaber S, et al.
Mitochondrion
. 2010 Dec;
11(3):421-9.
PMID: 21167961
We studied the functional properties of isolated brain mitochondria (BM) prepared from total rat brain (BM(total)) or from cerebral subregions under basal and Ca(2+) overload conditions in order to evaluate...